论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Wang SJ, Wang Q, Zhang X, Liao X, Wang G, Yu L, Zhang W, Zhou Q, Hu S, Yuan W
Received 8 August 2018
Accepted for publication 12 October 2018
Published 16 November 2018 Volume 2018:10 Pages 5807—5824
DOI https://doi.org/10.2147/CMAR.S183062
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Antonella D'Anneo
Background: Colon
adenocarcinoma (COAD) is ranked as the third most commonly diagnosed cancer in
both women and men, and it is the most frequently occurring malignant tumor.
Dynactin is a protein compound based on multiple subunits, including dynactin
1–6 (DCTN1–6), in most categories of cytoplasmic dynein performance in
eukaryotes. Nevertheless, correlations between the DCTN family and the
prognosis and diagnosis of COAD remain unidentified.
Methods: Statistics
for DCTN mRNA expression in patients with COAD were acquired from The Cancer
Genome Atlas. Kaplan–Meier analyses and a Cox regression model were applied to determine
overall survival, with computation of HRs and 95% CIs. Several online data
portals were used to assess the biological process, and pathway examination was
performed using the Kyoto Encyclopedia of Genes and Genomes to predict the
biological functionality of DCTN genes.
Results: We found
that high expression of DCTN4 was linked with satisfactory results for overall
survival (P =0.042,
HR=0.650, 95% CI 0.429–0.985). The expression of DCTN1 , DATN2 ,
and DCTN4 was
closely correlated with the frequency of colon tumors (P <0.001, area
under the curve [AUC]=0.8811, 95% CI 0.8311–0.9312; P <0.001,
AUC=0.870, 96% CI 0.833–0.9071; and P =0.0051, AUC=0.6317, 95% CI 0.5725–0.6908,
respectively). In the enrichment examination, the level of gene expression was
related to the cell cycle, cell apoptosis, and the cell metastasis pathway.
Conclusion: The expression
levels of DCTN1 ,
DCTN2 , and DCTN4 could allow differentiation between
cancer-bearing tissues and paracancerous tissue. These genes can be applied as
biomarkers to predict the prognosis and diagnosis of COAD.
Keywords: dynactin,
colon adenocarcinoma, diagnosis, prognosis, biomarker